Anika Therapeutics
ANIK
156 hedge funds and large institutions have $481M invested in Anika Therapeutics in 2020 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 51 increasing their positions, 49 reducing their positions, and 20 closing their positions.
5,276% more call options, than puts
Call options by funds: $26.1M | Put options by funds: $485K
4% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 49
1% less funds holding
Funds holding: 158 → 156 (-2)
2.5% less ownership
Funds ownership: 98.21% → 95.71% (-2.5%)
8% less capital invested
Capital invested by funds: $523M → $481M (-$42.1M)
10% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 20
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
Top Sellers
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$7.78M |
| 2 |
State Street
Boston,
Massachusetts
|
-$5.32M |
| 3 |
Prudential Financial
Newark,
New Jersey
|
-$3.8M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.09M |
| 5 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$3.06M |
ANIK Hedge Fund Activity: Q3 2020 in Review
156 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q3 2020, worth a combined $481M — down 8% from $523M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of ANIK and 18 opened new positions — a net loss of 2 holders — while 49 trimmed existing stakes and 51 added.
The largest buyer was Avidity Partners Management, adding an estimated $8.64M. The largest seller was Acadian Asset Management, cutting an estimated $7.78M.
- 156 institutional investors held Anika Therapeutics (ANIK) as of Q3 2020, down from 158 in Q2 2020.
- Funds reported $481M of Anika Therapeutics stock for Q3 2020, down 8% quarter-over-quarter.
- 18 funds opened new Anika Therapeutics positions in Q3 2020 and 20 closed out, a net change of -2 holders.
- The largest Anika Therapeutics buyer in Q3 2020 was Avidity Partners Management, an estimated $8.64M added.
- The largest Anika Therapeutics seller in Q3 2020 was Acadian Asset Management, an estimated $7.78M sold.
Based on aggregated 13F filings for Q3 2020.